<?xml version="1.0" encoding="UTF-8"?>
<p>Data from ongoing studies (
 <xref rid="T1" ref-type="table">
  <bold>Table 1</bold>
 </xref>) is expected to clarify the best timing, best IFN and best benefit compared with other molecules directed against SARS-CoV-2. In the meantime, IFN-based therapies in SARS-CoV-2 administered through aerosols (
 <xref rid="B83" ref-type="bibr">Sallard et al., 2020</xref>) (ChiCTR2000029638) or subcutaneously (IFNβ1b-NCT04276688/IFNβ1a-NCT04315948) should be closely supervised and require a very careful interpretation. Presently, various types of IFN are currently investigated in over 52 clinical trials in COVID-19 patients according to the Cochrane database.
</p>
